Loading…
Uses generative AI to design novel protein-based medicines across multiple disease areas.
Uses generative AI to design novel protein-based medicines across multiple disease areas.
Has no approved medicine yet; income so far has come from upfront and milestone payments under partnerships such as those with Novartis and Amgen, with the rest funded by investors. Its approach is to design proteins by computer and test them in the lab, feeding results back into the models.
Moat: narrow (data, IP / patents, process know-how). Generative AI platform for de novo protein design, backed by Flagship Pioneering and a Novartis partnership.
Headquarters: Somerville, Massachusetts, US · Founded: 2018 · Employees: 312
Size Generate Biomedicines (GENB) is a United States Health Care company (Biotechnology) with a market value of $1.68B, the 1913th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.06 on 6 Nov 2026.
Performance Over six months the shares fell 4.4%, against -7.4% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 18 in its peer set.
Growth Revenue grew 55.9% over the last twelve months (peer median +21.1%); the operating margin is -737.0% (peer median -36.0%).
Valuation It trades at 40.2× enterprise value to sales against a peer median of 14.8× (6th most expensive of 18).
Short interest Short interest is 7.0% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $31.9M | $20.5M |
| Revenue growth | — | +56% | — |
| Gross profit | n/a | $18.7M | $5.11M |
| EBITDA | n/a | -$222M | -$182M |
| Net income | n/a | -$203M | -$174M |
| Free cash flow | n/a | -$204M | -$121M |
| Capital expenditure | n/a | $3.51M | $3.45M |
| Total debt | $62.6M | $68.5M | $77.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Generate Biomedicines GENB | $1.68B | -4% | +56% | -737% | 40.2× | n/a |
| Absci ABSI | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a |
| Recursion Pharmaceuticals RXRX | $2.19B | +6% | +56% | -725% | 25.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GENB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -9.9% | 9th highest of 20 |
| 6-month return | -4.4% | -7.4% | 8th highest of 18 |
| Distance from 52-week high | -42.4% | -38.6% | 9th lowest of 20 |
| Revenue growth (TTM) | +55.9% | +21.1% | 7th highest of 19 |
| Operating margin | -737.0% | -36.0% | 4th lowest of 19 |
| EV / Sales | 40.2× | 14.8× | 6th most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |